Cargando…

Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations

Myelodysplastic syndromes (MDS) are often accompanied by autoimmune phenomena. The underlying mechanisms for these associations remain uncertain, although T cell activation seems to be important. Human T-lymphotropic virus (HTLV-1) has been detected in patients with myelodysplastic syndromes, mostly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diamantopoulos, Panagiotis T, Michael, Maria, Benopoulou, Olga, Bazanis, Efthymia, Tzeletas, George, Meletis, John, Vayopoulos, George, Viniou, Nora-Athina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305386/ https://www.ncbi.nlm.nih.gov/pubmed/22214262 http://dx.doi.org/10.1186/1743-422X-9-1

Ejemplares similares

A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients
por: Spetsieris, Nikolaos, et al.
Publicado: (2018)

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)
por: Kotsianidis, Ioannis, et al.
Publicado: (2019)

The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
por: Kontandreopoulou, Christina-Nefeli, et al.
Publicado: (2022)

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
por: Diamantopoulos, Panagiotis, et al.
Publicado: (2019)

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome
por: Kontandreopoulou, Christina-Nefeli, et al.
Publicado: (2021)

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2021)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

Deregulation of Autophagy and Apoptosis in Patients with Myelodysplastic Syndromes: Implications for Disease Development and Progression
por: Tsekoura, Georgia, et al.
Publicado: (2023)

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

PB1992: PROTEOMIC ANALYSIS REVEALS AUTOPHAGY INHIBITION IN MYELODYSPLASTIC SYNDROMES
por: Tsekoura, Georgia, et al.
Publicado: (2023)

A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy
por: Papaxoinis, George, et al.
Publicado: (2020)

An unusual case report of unilateral parotid gland sarcoidosis with spontaneous remission
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2019)

A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine
por: HISASUE, Masaharu, et al.
Publicado: (2021)

PARP1-Driven Apoptosis in Chronic Lymphocytic Leukemia
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2014)

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses
por: Konopleva, Marina, et al.
Publicado: (2023)

Pseudogout: An Autoimmune Paraneoplastic Manifestation of Myelodysplastic Syndrome
por: Iqbal, Shumaila M, et al.
Publicado: (2018)

A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis
por: Charakopoulos, Emmanouil, et al.
Publicado: (2020)

Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2020)

Bacillus Cereus in Hematological Malignancies
por: Markouli, Mariam, et al.
Publicado: (2022)

A Patient with Synchronous Gallbladder and Bone Plasmacytoma
por: Markouli, Mariam, et al.
Publicado: (2023)

Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
por: Tibes, Raoul, et al.
Publicado: (2015)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome
por: MELCHARDT, THOMAS, et al.
Publicado: (2013)

The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes
por: Murakami, Yuichi, et al.
Publicado: (2019)

HTLV-1, Immune Response and Autoimmunity
por: Quaresma, Juarez A S, et al.
Publicado: (2015)

Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study
por: Liapis, Konstantinos, et al.
Publicado: (2020)

Autoimmune manifestations associated with myelodysplastic syndrome predict a poor prognosis
por: Arinobu, Yojiro, et al.
Publicado: (2021)

Isolated skeletal muscle recurrence of an originally nodal diffuse large B cell lymphoma: A case report and review of the literature
por: Spetsieris, Nikolaos, et al.
Publicado: (2018)

5-Azacytidine restores interleukin 6-increased production in mesenchymal stromal cells from myelodysplastic patients
por: Boada, Matilde, et al.
Publicado: (2021)

Are We Identifying Malnutrition in Hospitalized Patients with Hematologic Malignancies? Results from a Quality Clinical Audit
por: Kanioura, Eftychia, et al.
Publicado: (2022)

JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature
por: Chatzidavid, Sevastianos, et al.
Publicado: (2021)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome
por: Sohlberg, Ebba, et al.
Publicado: (2015)

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle
por: Wang, Xiaobo, et al.
Publicado: (2023)

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine
por: Cabezón, Marta, et al.
Publicado: (2018)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Diagnosis and treatment complications of primary cardiac lymphoma in an immunocompetent 28-year old man: a case report
por: Bonou, Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l3r62fqhb3odudc6j9qdm8q891